Histrelin
- Generic Name
- Histrelin
- Brand Names
- Supprelin
- Drug Type
- Small Molecule
- Chemical Formula
- C70H94N18O16
- CAS Number
- 76712-82-8
- Unique Ingredient Identifier
- H50H3S3W74
- Background
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs con...
- Indication
As the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP). As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer, Central Precocious Puberty (CPP)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath